Elicio Therapeutics Closes $15M Registered Direct Offering, Funds Clinical Development
ELTX sits 23% above its 52-week low of $2.66.
Summary
Elicio Therapeutics has closed its previously announced $15 million registered direct offering, securing approximately $15 million in gross proceeds from the sale of 4,380,313 shares. This follows the pricing announcement on July 2nd and provides crucial funding for the company. The proceeds will primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and other pipeline activities, as well as general corporate purposes. This capital raise is significant for the company, which had previously issued a "going concern" warning and recently reported a Phase 2 trial miss for its lead pancreatic cancer drug.
At the time of this announcement, ELTX was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.9M. The 52-week trading range was $2.66 to $16.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.